Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Biocon Limited ( (IN:BIOCON) ).
Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received U.S. Food and Drug Administration approval for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension in 2 mg, 3 mg and 5 mg strengths, indicated for the treatment of adult and pediatric patients with Tuberous Sclerosis Complex-related Subependymal Giant Cell Astrocytoma and as adjunctive therapy for TSC-associated partial-onset seizures. The approval adds a specialized central nervous system and oncology-related therapy to Biocon’s U.S. generics portfolio, further strengthening its vertically integrated drug product franchise and supporting its strategy to expand presence in complex, high-value segments of the regulated generics market.
More about Biocon Limited
Biocon Limited is an India-based biopharmaceutical company focused on developing and manufacturing complex generics, biosimilars and other specialty pharmaceutical products for global markets, including the U.S. Biocon Pharma Limited, its wholly owned subsidiary, handles vertically integrated drug product development and commercialization, reinforcing the group’s positioning in regulated markets such as the United States.
Average Trading Volume: 146,893
Technical Sentiment Signal: Buy
Current Market Cap: 506.6B INR
See more insights into BIOCON stock on TipRanks’ Stock Analysis page.